tirzepatide 7 5 mg Zepbound 7.5 mg/0.5 mL injection (single-dose vial) Images Tirzepatide / Glycine – WP

Nearly two months of waiting for a medication that requires consistent weekly dosing to maintain therapeutic levels

A BMI of 27 or greater (classified as overweight) in the presence of at least one weight-related medical condition, such as hypertension (high blood pressure), Type 2 diabetes, or high cholesterol

Clinical findings suggest the long-term effectiveness and safety of semaglutide as a weight loss agent in non-diabetics, with sustained weight loss over a two-year period and few hypoglycemic events noted

Which of these patient-specific factors (e.g., BMI, A1C, comorbidities) make this patient a good candidate for semaglutide